Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MC4R biased agonist (Superluminal Medicines)
- Development stage
- Unknown
- Lead developer
- Superluminal Medicines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Superluminal Medicines is developing an orally administered, small-molecule biased agonist of the melanocortin 4 receptor (MC4R). This compound is engineered to selectively activate specific signaling pathways within the MC4R system, which is a critical regulator of energy homeostasis and appetite. By utilizing a biased signaling approach, the drug aims to achieve therapeutic efficacy in weight management while avoiding common side effects associated with non-selective MC4R activation. The program is initially targeting rare genetic conditions such as Bardet-Biedl Syndrome (BBS) and hypothalamic obesity, with future potential for treating general obesity, including in combination with GLP-1 receptor agonists. An IND submission for the program is anticipated in the second half of 2026.
- Other names
- MC4R programMC-4R programMC 4R programbiased MC4R agonist
02
Targets
MC4R (Melanocortin 4 receptor)
Beyond the preview
Go deeper on MC4R biased agonist (Superluminal Medicines).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MC4R biased agonist (Superluminal Medicines).